阿尔茨海默病:未来的治疗挑战
John Hardy1,2
1Department of Neurodegenerative Disease, UCL Institute of Neurology, United Kingdom.
Journal of neurochemistry
|July 31, 2025
概括
针对阿尔茨海默病的第一个抗粉样蛋白抗体 - - 莱卡内马布和多纳内马布 - - 是一个重大进步. 未来的研究将专注于改进这些疗法,并了解阿尔茨海默病的发病因子.
科学领域:
- 神经学 神经学
- 免疫治疗是一种免疫疗法.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病是一种流行的神经退行性疾病,有效治疗方法有限.
- 最近对抗粉样蛋白抗体的批准标志着治疗策略的重大转变.
- 莱卡尼马布和多纳尼马布是第一个针对粉样蛋白病理的疾病修饰疗法.
研究的目的:
- 审查新的抗粉样抗体疗法对阿尔茨海默氏症病原学的影响.
- 讨论未来发展更安全,更有效的阿尔茨海默病治疗方法的方向.
- 强调需要在药物开发,生物标志物和神经病理学方面继续进行研究.
主要方法:
- 对阿尔茨海默病的抗粉样抗体治疗现有文献的综述.
- 分析lecanemab和donanemab对疾病理解和临床实践的影响.
- 讨论阿尔茨海默病治疗的未来研究重点.
主要成果:
- 莱卡尼马布和多纳尼马布的推出意味着阿尔茨海默病治疗的新时代.
- 这些疗法提供了关于粉样蛋白在疾病发病过程中的作用的见解.
- 目前的疗法是不完美的,需要进一步的进步.
结论:
- 抗粉样蛋白抗体代表了阿尔茨海默氏症治疗和发病研究的突破.
- 未来的研究应该优先考虑减少副作用,通过生物标志物早期识别患者,并了解治疗机制.
- 目标是实现对阿尔茨海默病的安全,有效和疾病停止疗法.
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100


